Prometheus Laboratories has launched three microRNA-based diagnostics: ProOnc TumorSource Dx, ProOnc Squamous Dx, and ProOnc Mesothelioma Dx.
According to the company, the first identifies the tissue-of-origin of a metastatic tumor; the second classifies non-small cell lung carcinoma tumors into two histological groups: cancers of squamous histology and non-squamous cancers; and the third differentiates malignant pleural mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and pleura.
The tests were formerly known as miRview Mets, miRview Squamous, and miRview Meso, and were developed by Rosetta Genomics. In April, Rosetta agreed to license the US rights to the products to Prometheus (see RNAi News, 4/16/2009). The deal closed a few weeks later.